Table Graph
      published meta-analysis   sensitivity analysis   studies

Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19) in COVID-19 prophylaxis (excluding children) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 0.20 [0.02; 1.72] 0.20[0.02; 1.72]ChAdOx1 phase 3 (AstraZeneca), 202010%11,636NAnot evaluable symptomatic Covid-19detailed resultsAstraZeneca phase 3 US (D8110C00001), 2021 0.24 [0.18; 0.32] ChAdOx1 phase 3 (AstraZeneca), 2020 0.33 [0.26; 0.43] 0.29[0.21; 0.39]AstraZeneca phase 3 US (D8110C00001), 2021, ChAdOx1 phase 3 (AstraZeneca), 2020265%17,177lownot evaluable asymptomatic COVID casedetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 0.33 [0.23; 0.48] 0.33[0.23; 0.48]ChAdOx1 phase 3 (AstraZeneca), 202010%11,636NAnot evaluable infection (PCR positive symptomatic or not)detailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 0.44 [0.33; 0.59] 0.44[0.33; 0.59]ChAdOx1 phase 3 (AstraZeneca), 202010%11,636NAnot evaluable severe COVID-19 occurrencedetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 0.49 [0.02; 14.54] 0.49[0.02; 14.54]ChAdOx1 phase 3 (AstraZeneca), 202010%23,745NAnot evaluable vaccine efficacy after dose 1 (and before dose 2)detailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 0.24 [0.14; 0.41] 0.24[0.14; 0.41]ChAdOx1 phase 3 (AstraZeneca), 202010%18,494NAnot evaluable serious adverse eventsdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 0.86 [0.64; 1.17] 0.86[0.64; 1.17]ChAdOx1 phase 3 (AstraZeneca), 202010%23,745NAnot evaluable adverse eventsdetailed resultsAsano, 2022 1.44 [0.71; 2.93] AstraZeneca phase 3 US (D8110C00001), 2021 1.62 [1.54; 1.71] Com-COV, 2021 1.14 [0.78; 1.66] Com-COV2, 2022 1.14 [0.82; 1.59] 1.37[1.07; 1.74]Asano, 2022, AstraZeneca phase 3 US (D8110C00001), 2021, Com-COV, 2021, Com-COV2, 2022460%34,170NAnot evaluable ATE (Myocardial infarction or ischemic stroke)detailed resultsAstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020 0.44 [0.15; 1.27] AstraZeneca phase 3 US (D8110C00001), 2021 0.12 [0.01; 2.77] 0.39[0.14; 1.06]AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020, AstraZeneca phase 3 US (D8110C00001), 202120%56,623NAnot evaluable Guillain-Barré syndrome detailed resultsAstraZeneca phase 3 US (D8110C00001), 2021 1.00 [0.03; 29.81] 1.00[0.03; 29.81]AstraZeneca phase 3 US (D8110C00001), 202110%32,379NAnot evaluable intracranial hemorrhage detailed resultsAsano, 2022 0.33 [0.01; 16.88] AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020 0.24 [0.01; 5.40] AstraZeneca phase 3 US (D8110C00001), 2021 0.50 [0.01; 25.21] Com-COV, 2021 1.01 [0.02; 51.28] Com-COV2, 2022 4.97 [0.10; 251.14] 0.65[0.12; 3.39]Asano, 2022, AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020, AstraZeneca phase 3 US (D8110C00001), 2021, Com-COV, 2021, Com-COV2, 202250%58,414NAnot evaluable ischemic strokedetailed resultsAsano, 2022 0.33 [0.01; 16.88] AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020 0.32 [0.03; 3.12] AstraZeneca phase 3 US (D8110C00001), 2021 0.13 [0.01; 2.77] Com-COV, 2021 1.01 [0.02; 51.28] Com-COV2, 2022 2.48 [0.08; 74.26] 0.44[0.11; 1.76]Asano, 2022, AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020, AstraZeneca phase 3 US (D8110C00001), 2021, Com-COV, 2021, Com-COV2, 202250%58,414NAnot evaluable Myocardial infarction detailed resultsAsano, 2022 0.33 [0.01; 16.88] AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020 0.24 [0.03; 2.18] AstraZeneca phase 3 US (D8110C00001), 2021 0.25 [0.01; 7.46] Com-COV, 2021 1.01 [0.02; 51.28] Com-COV2, 2022 9.96 [0.33; 298.06] 0.57[0.14; 2.31]Asano, 2022, AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020, AstraZeneca phase 3 US (D8110C00001), 2021, Com-COV, 2021, Com-COV2, 202250%58,414NAnot evaluable pulmonary embolismdetailed resultsAsano, 2022 0.33 [0.01; 16.88] AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020 0.49 [0.02; 14.52] AstraZeneca phase 3 US (D8110C00001), 2021 0.50 [0.01; 25.21] Com-COV, 2021 1.01 [0.02; 51.28] Com-COV2, 2022 4.97 [0.10; 251.14] 0.81[0.15; 4.42]Asano, 2022, AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020, AstraZeneca phase 3 US (D8110C00001), 2021, Com-COV, 2021, Com-COV2, 202250%58,414NAnot evaluable serious adverse events (SAE), anydetailed resultsAsano, 2022 0.16 [0.01; 4.96] AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020 0.83 [0.64; 1.07] AstraZeneca phase 3 US (D8110C00001), 2021 0.95 [0.68; 1.33] 0.87[0.71; 1.06]Asano, 2022, AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020, AstraZeneca phase 3 US (D8110C00001), 202130%56,879NAnot evaluable venous thromboembolism detailed resultsAstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020 0.24 [0.01; 5.40] Com-COV2, 2022 2.48 [0.08; 74.26] 0.70[0.07; 6.90]AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020, Com-COV2, 202220%25,316NAnot evaluable Bell's palsydetailed resultsAstraZeneca phase 3 US (D8110C00001), 2021 1.00 [0.03; 29.81] ChAdOx1 phase 3 (AstraZeneca), 2020 0.98 [0.20; 4.83] 0.98[0.23; 4.17]AstraZeneca phase 3 US (D8110C00001), 2021, ChAdOx1 phase 3 (AstraZeneca), 202020%56,124moderatenot evaluable immediate allergic reactiondetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 1.95 [0.07; 58.15] 1.95[0.07; 58.15]ChAdOx1 phase 3 (AstraZeneca), 202010%23,745NAnot evaluable multiple sclerosisdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 1.95 [0.07; 58.15] 1.95[0.07; 58.15]ChAdOx1 phase 3 (AstraZeneca), 202010%23,745NAnot evaluable myelitisdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 1.95 [0.18; 21.52] 1.95[0.18; 21.52]ChAdOx1 phase 3 (AstraZeneca), 202010%23,745NAnot evaluable Potential Immune Gastrointestinal disordersdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 0.33 [0.03; 3.13] 0.33[0.03; 3.13]ChAdOx1 phase 3 (AstraZeneca), 202010%23,745NAnot evaluable Potential Immune Musculoskeletal disordersdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 0.98 [0.06; 15.60] 0.98[0.06; 15.60]ChAdOx1 phase 3 (AstraZeneca), 202010%23,745NAnot evaluable Potential Immune Neuroinflammatory disordersdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 1.22 [0.33; 4.54] 1.22[0.33; 4.54]ChAdOx1 phase 3 (AstraZeneca), 202010%23,745NAnot evaluable Potential Immune Skin disordersdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 0.73 [0.16; 3.27] 0.73[0.16; 3.27]ChAdOx1 phase 3 (AstraZeneca), 202010%23,745NAnot evaluable Potential Immune Vasculitidesdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 0.49 [0.02; 14.54] 0.49[0.02; 14.54]ChAdOx1 phase 3 (AstraZeneca), 202010%23,745NAnot evaluable Thromboembolic eventsdetailed resultsChAdOx1 phase 3 (AstraZeneca), 2020 0.49 [0.15; 1.62] 0.49[0.15; 1.62]ChAdOx1 phase 3 (AstraZeneca), 202010%23,745NAnot evaluable0.05.01.0relative treatment effectwww.metaEvidence.org2024-05-02 14:29 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 89 - treatments: 759 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons